Cargando…
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study
PURPOSE: Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the di...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398105/ https://www.ncbi.nlm.nih.gov/pubmed/25483747 http://dx.doi.org/10.4143/crt.2014.015 |
_version_ | 1782366784132743168 |
---|---|
author | Tsaur, Igor Noack, Anika Makarevic, Jasmina Oppermann, Elsie Waaga-Gasser, Ana Maria Gasser, Martin Borgmann, Hendrik Huesch, Tanja Gust, Kilian M. Reiter, Michael Schilling, David Bartsch, Georg Haferkamp, Axel Blaheta, Roman A. |
author_facet | Tsaur, Igor Noack, Anika Makarevic, Jasmina Oppermann, Elsie Waaga-Gasser, Ana Maria Gasser, Martin Borgmann, Hendrik Huesch, Tanja Gust, Kilian M. Reiter, Michael Schilling, David Bartsch, Georg Haferkamp, Axel Blaheta, Roman A. |
author_sort | Tsaur, Igor |
collection | PubMed |
description | PURPOSE: Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa. MATERIALS AND METHODS: Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested. RESULTS: The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading. CONCLUSION: Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker. |
format | Online Article Text |
id | pubmed-4398105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-43981052015-04-16 CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study Tsaur, Igor Noack, Anika Makarevic, Jasmina Oppermann, Elsie Waaga-Gasser, Ana Maria Gasser, Martin Borgmann, Hendrik Huesch, Tanja Gust, Kilian M. Reiter, Michael Schilling, David Bartsch, Georg Haferkamp, Axel Blaheta, Roman A. Cancer Res Treat Original Article PURPOSE: Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa. MATERIALS AND METHODS: Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested. RESULTS: The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading. CONCLUSION: Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker. Korean Cancer Association 2015-04 2014-10-13 /pmc/articles/PMC4398105/ /pubmed/25483747 http://dx.doi.org/10.4143/crt.2014.015 Text en Copyright © 2015 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Tsaur, Igor Noack, Anika Makarevic, Jasmina Oppermann, Elsie Waaga-Gasser, Ana Maria Gasser, Martin Borgmann, Hendrik Huesch, Tanja Gust, Kilian M. Reiter, Michael Schilling, David Bartsch, Georg Haferkamp, Axel Blaheta, Roman A. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study |
title | CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study |
title_full | CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study |
title_fullStr | CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study |
title_full_unstemmed | CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study |
title_short | CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study |
title_sort | ccl2 chemokine as a potential biomarker for prostate cancer: a pilot study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398105/ https://www.ncbi.nlm.nih.gov/pubmed/25483747 http://dx.doi.org/10.4143/crt.2014.015 |
work_keys_str_mv | AT tsaurigor ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT noackanika ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT makarevicjasmina ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT oppermannelsie ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT waagagasseranamaria ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT gassermartin ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT borgmannhendrik ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT hueschtanja ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT gustkilianm ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT reitermichael ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT schillingdavid ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT bartschgeorg ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT haferkampaxel ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy AT blahetaromana ccl2chemokineasapotentialbiomarkerforprostatecancerapilotstudy |